View Post

Keytruda and Chemotherapy Combination Broadens Number of Treatable Patients with TNBC

In In The News by Barbara Jacoby

By: Conor Killmurray From: curetoday.com In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer. In November, the Food and Drug Administration (FDA) granted …

View Post

Evelo Biosciences, Inc. Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in Patients with Triple-Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

Source: Evelo Biosciences, Inc. From: globenewswire.com –EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503– –Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity– Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines which act in the small intestine …

View Post

Dr. Kalinsky on Initial Results of the RxPONDER Trial in HR+/HER2- Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Kevin Kalinsky, MD, MS From: onclive.com Kevin Kalinsky, MD, MS, director of the Glenn Family Breast Center and Breast Medical Oncology at Winship Cancer Institute, and acting associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, discusses the initial results of the phase 3 RxPONDER trial in patients with hormone receptor (HR)–positive, …

View Post

Postoperative Radiotherapy Can Be Omitted Without Impacting Metastatic Risk in Low-Grade Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Tony Berberabe From: onclive.com Whole breast irradiation (WBI), following breast-conserving surgery and adjuvant endocrine therapy, can be omitted from the treatment journey of low-risk, older patients with pT1-2 tumors (≥3 cm) who are on local control at 10 years, according to data from the PRIME 2 trial (ISRCTN9588932) presented during the 2020 San Antonio Breast Cancer Symposium.1 Investigators made …

View Post

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

In Clinical Trials by Barbara Jacoby

From: .businesswire.com Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy in …

View Post

Should All Breast Cancer Patients Receive Genetic Testing?

In In The News by Barbara Jacoby

By: Jaime Rosenberg From: ajmc.com Recent years have seen calls for genetic testing for all patients with breast cancer. A session at the 2020 San Antonio Breast Cancer Symposium reviewed the evidence for, and against, such testing. In light of the 30th anniversary of Mary-Claire King, PhD, mapping BRCA1, a session on the last day of the 2020 San Antonio …

View Post

Good clinical outcomes only a part of breast cancer recovery

In In The News by Barbara Jacoby

From: sabcsmeetingnews.org Recovering from breast cancer means more than good clinical outcomes. The overarching goal is good quality of life, which means balancing clinical outcomes with treatment toxicities while preserving a positive body image, good sexual health and, for patients who want it, the opportunity for biological children. “Local therapy can cause pain and lymphedema while systemic treatment can cause …

View Post

Educational Session explores advances in treating ER positive breast cancer

In In The News by Barbara Jacoby

From: sabcsmeetingnews.org Estrogen receptor positive (ER+) breast cancers may represent the single largest unmet clinical need in the field. ER+ breast cancer, also called luminal breast cancer, was once considered the default type of breast cancer, said David A. Cameron, MD, MSc. “Luminal breast cancer is the commonest type of breast cancer we see worldwide, about three-quarters of all breast …

View Post

Low-Risk Recurrence Scores Classified Accurately With AI-Digital Breast Cancer Risk Assessment Platform

In Clinical Trials by Barbara Jacoby

By: Hayley Virgil From: targetedonc.com Patients with Oncotype Dx low-risk recurrence scores were classifed with high accuracy by the artificial intelligence (AI)-digital breast cancer risk discrimination platform PreciseDx by using only hematoxylin and eosin stain (H&E) images and limited clinical data, according to findings presented during the 2020 San Antonio Breast Cancer Symposium.1 Results showed that the PreciseDx model, which …

View Post

Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020

In In The News by Barbara Jacoby

From: businesswire.combreast Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Latest findings from the breast cancer cohort in SUMMIT – a phase 2 ‘basket’ trial of neratinib + trastuzumab + …